Previous Article | Next Article 
Journal of Virology, July 2001, p. 5939-5948, Vol. 75, No. 13
Laboratoire de
Rétrovirologie1 and Centre de
Primatologie,6 Institut Pasteur de la Guyane,
Cayenne, French Guiana; Unité d'Oncologie Virale,
Institut Pasteur, Paris, France2;
Aventis-Pasteur, Toronto, Ontario,
Canada3; Virogenetics Corporation, Troy, New
York4; and Division of Basic Sciences,
National Cancer Institute, National Institutes of Health, Bethesda,
Maryland5
Received 12 June 2000/Accepted 30 March 2001
We assessed the immunogenicities and efficacies of two highly
attenuated vaccinia virus-derived NYVAC vaccine candidates encoding the
human T-cell leukemia/lymphoma virus type 1 (HTLV-1) env
gene or both the env and gag genes in
prime-boost pilot regimens in combination with naked DNA expressing the
HTLV-1 envelope. Three inoculations of NYVAC HTLV-1 env
at 0, 1, and 3 months followed by a single inoculation of DNA
env at 9 months protected against intravenous challenge
with HTLV-1-infected cells in one of three immunized squirrel monkeys.
Furthermore, humoral and cell-mediated immune responses against HTLV-1
Env could be detected in this protected animal. However, priming the
animal with a single dose of env DNA, followed by
immunization with the NYVAC HTLV-1 gag and
env vaccine at 6, 7, and 8 months, protected all three
animals against challenge with HTLV-1-infected cells. With this
protocol, antibodies against HTLV-1 Env and cell-mediated responses
against Env and Gag could also be detected in the protected animals.
Although the relative superiority of a DNA prime-NYVAC boost regimen
over addition of the Gag component as an immunogen cannot be assessed directly, our findings nevertheless show that an HTLV-1 vaccine approach is feasible and deserves further study.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.5939-5948.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Immunogenicity and Protective Efficacy of
Recombinant Human T-Cell Leukemia/Lymphoma Virus Type 1 NYVAC
and Naked DNA Vaccine Candidates in Squirrel Monkeys
(Saimiri sciureus)
*
Corresponding author. Mailing address: Laboratoire de
Rétrovirologie, Institut Pasteur de la Guyane, B.P. 6010, 23 Av.
Pasteur, 97306 Cayenne, French Guiana. Phone: 0594 29 68 44. Fax: 0594 30 94 16. E-mail: mkazanji{at}pasteur-cayenne.fr.
Journal of Virology, July 2001, p. 5939-5948, Vol. 75, No. 13
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.5939-5948.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kazanji, M., Heraud, J.-M., Merien, F., Pique, C., de The, G., Gessain, A., Jacobson, S.
(2006). Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus).. J. Gen. Virol.
87: 1331-1337
[Abstract] [Full Text] -
Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., Bilska, M., Kothe, D. L., Salazar-Gonzalez, J. F., Wei, X., Decker, J. M., Hahn, B. H., Montefiori, D. C.
(2005). Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. J. Virol.
79: 10108-10125
[Abstract] [Full Text]
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»